Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide.
Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor
acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The
studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor
monotherapy in preventing major vascular events in patients with AIS or TIA. The results
showed that the number of patients with endpoint events in ticagrelor group was less than
that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than
ASA. The purpose of this study is to prove that ticagrelor is better than ASA.